Traub Capital Management LLC Acquires New Position in Jazz Pharmaceuticals PLC $JAZZ

Traub Capital Management LLC acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $106,000.

A number of other institutional investors also recently modified their holdings of JAZZ. LSV Asset Management raised its stake in Jazz Pharmaceuticals by 3.6% during the second quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after buying an additional 87,576 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after acquiring an additional 293,360 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Jazz Pharmaceuticals by 4.7% in the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company’s stock valued at $206,343,000 after purchasing an additional 74,501 shares during the period. Fuller & Thaler Asset Management Inc. grew its stake in Jazz Pharmaceuticals by 41.7% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after purchasing an additional 391,660 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Jazz Pharmaceuticals by 1.5% in the second quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company’s stock worth $124,366,000 after purchasing an additional 16,757 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares in the company, valued at $55,303,127.26. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Robert Iannone sold 7,159 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $168.26, for a total transaction of $1,204,573.34. Following the completion of the sale, the executive vice president owned 72,628 shares in the company, valued at approximately $12,220,387.28. This trade represents a 8.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 18,659 shares of company stock worth $2,729,853 over the last ninety days. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.5%

Jazz Pharmaceuticals stock opened at $176.08 on Thursday. The firm has a market capitalization of $10.70 billion, a price-to-earnings ratio of -26.16, a P/E/G ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $182.99. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The firm has a 50 day simple moving average of $136.90 and a 200 day simple moving average of $121.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.87 by $2.26. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same quarter last year, the company earned $6.54 earnings per share. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on JAZZ. Wells Fargo & Company raised their price target on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday. JPMorgan Chase & Co. decreased their price target on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a report on Monday, October 27th. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Finally, The Goldman Sachs Group increased their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $195.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.